Wednesday, January 20, 2021Canada's Leading Online Business Magazine

Field Trip Health Ltd. Announces Participation in a MAPS-sponsored Multi-Site Study of MDMA-Assisted Therapy to Treat Eating Disorders

Field Trip Health Ltd

TORONTO, Jan. 07, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) (“Field Trip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce it has, subject to completion of a final site inspection, been selected as a trial location for a MAPS-sponsored study on the safety, feasibility and preliminary outcomes of MDMA-assisted therapy to treat eating disorders (the “Eating Disorder Study”), including Anorexia Nervosa.
Anorexia Nervosa is a mental health condition and eating disorder characterized by low weight, food restriction, fear of gaining weight and a strong desire to be thin. Anorexia is also the most deadly mental illness, with a higher mortality (death) rate than any other mental illness, leading to potential cardiac complications, heart, kidney and liver failure, bone loss, anemia and suicide. Subject to the site inspection, Field Trip’s Toronto location will be used as the trial site for the Health Canada-approved Anorexia Nervosa arm of the Eating Disorder Study. Field Trip’s Canadian Medical Director, Dr. Michael Verbora, will act as the Qualified Investigator and Site Physician for this site. During the Anorexia arm of the Study, Field Trip will be hosting MAPS-trained therapists who will be providing MDMA-assisted therapy to an initial cohort of individuals suffering from Anorexia Nervosa, and collecting safety, feasibility and preliminary outcome data.In December, MAPS announced partial results of its first Phase 3 randomized, double-blind, placebo-controlled study assessing the safety and efficacy of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD). According to MAPS, the study generated statistically significant results demonstrating that MDMA-assisted therapy may be an effective treatment for PTSD resulting from various types of trauma, including trauma occurring in childhood and in patients with dissociative subtype of PTSD, pending assessment by the U.S. Food and Drug Administration (FDA). Further, no unexpected or serious safety signals emerged during the course of the trial.Field Trip Announces Annual Contribution to MAPS, Matching Contribution from FoundersField Trip also announced today that it is becoming a financial supporter of MAPS, committing to making an annual contribution of $50,000 to MAPS, a 501(c)(3) non-profit organization in the United States, which will be matched by a collective contribution from the founders of Field Trip on a dollar-for-dollar basis. Site selection is conducted independently by MAPS Public Benefit Corporation and is unaffected by charitable contributions to MAPS.“MAPS, led by Rick Doblin’s unique vision and relentless determination, has been at the forefront of the renaissance of psychedelics, pushing for scientific, regulatory and legal change for psychedelics for more than 30 years,” said Ronan Levy, Field Trip’s Executive Chairman. “The success of the Phase 3 PTSD trial is a pivotal achievement for MAPS, and a significant step forward for all people suffering from mental health conditions. We are pleased to be able to financially support MAPS both as an organization and individually, and we are honored to be conducting the critical work necessary to extend the reach of MDMA-assisted therapies to new indications such as Anorexia Nervosa.” “For-profit or non-profit, we are all together in seeking to bring new methods of psychedelic healing to those millions who need it,” said Rick Doblin, MAPS’ Founder and Executive Director.  “We greatly appreciate the generous support from Field Trip and its founders, and look forward to working with them as part of the Eating Disorder Study and beyond.  One of MAPS’ principles is that we don’t have competitors, just allies in the larger mission of contributing to mass mental health.”NOTEAbout Field Trip Health Ltd.Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world. Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nlFollow us on Twitter and Instagram: @fieldtriphealthTo receive company updates about Field Trip and to be added to the email distribution list please sign up here.ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Since its founding, MAPS has raised over $100 million for psychedelic therapy and medical marijuana research and education.www.maps.orgABOUT MAPS PUBLIC BENEFIT CORPORATION (MAPS PBC)www.mapspublicbenefit.orgCautionary Note Regarding Forward-Looking Information.The CSE has neither approved nor disapproved the contents of this news release.Media contacts:
Rachel Moskowitz
Autumn Communications
212-206-9780
rmoskowitz@autumncommunications.com / fieldtrip@autumncommunications.com
Investor contacts:
Elizabeth Barker
KCSA Strategic Communications
212-896-1203
ebarker@kcsa.com


CBJ Newsmakers

Recommended
Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D ActivitiesLeonovus Hyper-Secure Smart Data Management Provides Patented Data-Centric Protection for New Government Department